MERLIN:布西珠单抗治疗新生血管性年龄相关性黄斑变性伴持续性视网膜积液的3a期多中心随机双盲试验
MERLIN研究纳入既往频繁抗VEGF治疗后仍有持续性视网膜积液的新生血管性年龄相关性黄斑变性(nAMD)患眼,随机2:1接受布西珠单抗6 mg或阿柏西普2 mg每4周一次至第100周。第52周时布西珠单抗在最佳矫正视力(BCVA)变化上非劣于阿柏西普(最小二乘均值差-0.6个ETDRS字母,95%CI -2.1至0.9,P<0.001),且解剖学结局更优,但眼内炎症、视网膜血管炎和视网膜血管闭塞发生率更高,导致研究终止。
要点
- 布西珠单抗6 mg每4周一次在BCVA变化上非劣于阿柏西普2 mg每4周一次(LSM差-0.6字母,95%CI -2.1至0.9)。
- 第52周无积液比例布西珠单抗40.4% vs 阿柏西普19.0%(95%CI 13.9-29.0,P<0.001)。
- 布西珠单抗组眼内炎症发生率9.3%(视网膜血管炎0.8%、视网膜血管闭塞2.0%),阿柏西普组4.5%(均为0%),导致研究终止。
核心结论
- 在既往治疗且伴持续性视网膜积液的nAMD患眼中,布西珠单抗6 mg每4周一次的视力结局非劣于阿柏西普2 mg每4周一次,且解剖学结局更优。
- 但布西珠单抗组眼内炎症(包括视网膜血管炎和视网膜血管闭塞)发生率更高,导致研究终止。
研究设计与样本
- 多中心、随机、双盲3a期研究。
- 患眼按2:1随机接受玻璃体腔内注射布西珠单抗6 mg或阿柏西普2 mg,每4周一次,至第100周(含第100周)。
- 纳入既往频繁接受抗血管内皮生长因子(anti-VEGF)治疗但仍存在持续性残留视网膜积液的难治性nAMD参与者。
主要发现
- 第52周BCVA自基线变化的最小二乘均值差为-0.6个早期治疗糖尿病视网膜病变研究(ETDRS)字母(95%CI -2.1至0.9;P<0.001),布西珠单抗非劣于阿柏西普(非劣效界值4个字母)。
- 第52周BCVA较基线丢失≥15个字母的参与者比例:布西珠单抗组4.8% vs 阿柏西普组1.7%。
- 与阿柏西普组相比,布西珠单抗组中央亚区厚度(CST)显著降低(P<0.001)。
- 第52周无积液(无视网膜内积液且无视网膜下积液)的患眼比例:布西珠单抗组40.4% vs 阿柏西普组19.0%(95%CI 13.9-29.0;P<0.001)。
- 眼内炎症(IOI)发生率:布西珠单抗组9.3%(其中视网膜血管炎0.8%、视网膜血管闭塞2.0%)vs 阿柏西普组4.5%(视网膜血管炎0%、视网膜血管闭塞0%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the 52-week efficacy and safety of brolucizumab 6 mg administered every 4 weeks compared with aflibercept 2 mg dosed every 4 weeks in eyes with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid. DESIGN: Multicenter, randomized, double-masked phase 3a study. PARTICIPANTS: Participants with recalcitrant nAMD (persistent residual retinal fluid despite previous frequent anti-vascular endothelial growth factor treatment). METHODS: Eyes were randomized (2:1) to intravitreal brolucizumab 6 mg or aflibercept 2 mg every 4 weeks up to and including week 100. MAIN OUTCOME MEASURES: The primary end point was analysis of noninferiority in mean best-corrected visual acuity (BCVA) change from baseline to week 52 (margin, 4 letters). Other key end points included change in central subfield thickness (CST) from baseline to week 52, fluid-free status (no intraretinal fluid and no subretinal fluid), and safety. RESULTS: At week 52, brolucizumab was noninferior to aflibercept in BCVA change from baseline (least squares mean difference, -0.6 Early Treatment Diabetic Retinopathy Study letters; 95% confidence interval [CI], -2.1 to 0.9; P < 0.001). A total of 4.8% and 1.7% of participants reported a 15-letter or more BCVA loss from baseline at week 52 in the brolucizumab and aflibercept groups, respectively. In eyes treated with brolucizumab compared with those treated with aflibercept, the CST was reduced significantly (P < 0.001), and a significantly greater proportion of eyes were fluid free at week 52 (40.4% brolucizumab vs. 19.0% aflibercept; 95% CI, 13.9-29.0; P < 0.001). Incidence of intraocular inflammation (IOI), including retinal vasculitis and retinal vascular occlusion, were 9.3% (0.8% and 2.0%) for brolucizumab versus 4.5% (0% and 0%) for aflibercept, respectively. CONCLUSIONS: Visual acuity outcomes in previously treated participants with nAMD and persistent retinal fluid receiving brolucizumab 6 mg dosed every 4 weeks were noninferior to aflibercept 2 mg dosed every 4 weeks, with superior anatomic outcomes. However, incidences of IOI, including retinal vasculitis and retinal vascular occlusion, also were higher, leading to study termination.
引用
- Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022. PMID: 35537533. doi:10.1016/j.ophtha.2022.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。